Share-Based Payment (Tables)

12 Months Ended

Dec. 31, 2019

Share-Based Payment [Abstract]

Summary of number of share options and their related weighted average exercise prices

	Year ended December 31,
	2019				2018					2017
	Number of options		Weighted average exercise price (USD)		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
Outstanding at beginning of year		6,200,000		0.15		7,355,833			0.16		6,750,000			0.17
Granted		-		-		-			-		1,000,000			0.03
Exercised		-		-		-			-		-			-
Expired		-		-		(1,155,833	)		0.16		(40,000	)		0.21
Forfeited		-		-		-			-		(354,167	)		0.14
Outstanding at end of year		6,200,000		0.15		6,200,000			0.15		7,355,833			0.16
Exercisable at end of year		5,949,998		0.16		5,529,166			0.16		5,514,166			0.19

Summary of exercise price and the remaining contractual life (in years)

December 31,
2019				2018
Options outstanding at end of year		Range of exercise prices (USD)	Weighted average remaining contractual life	Options outstanding at end of year		Range of exercise prices (USD)	Weighted average remaining contractual life
	2,150,000	0 - 0.14	7.24		2,150,000	0 - 0.14	7.24
	4,050,000	0.15 -1.6	6.12		4,050,000	0.15 -1.6	6.12
	6,200,000				6,200,000

Summary of outstanding options

Options  outstanding		Position	Grant date (*)	Exercise price in NIS		Fair value USD		Vesting schedule
	900,000	Chief Executive Officer	October 15, 2013		0.9		143	12 equal portions each quarter over a period of 3 years from the grant date
	600,000	Chief Executive Officer	October 15, 2013		0.6		97	12 equal portions each quarter over a period of 3 years from the grant date
	600,000	Four Directors	December 30, 2014		0.4325		46	33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first
	150,000	Consultant	December 30, 2014		0.4915		12	33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first
	300,000	Two Directors	March 25, 2015		0.40		24	33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first
	100,000	Chief Executive Officer	March 25, 2015		0.4		7	33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first
	50,000	Medical Director	March 4, 2016		0.6		2	12 equal portions each quarter over a period of 3 years from the date of grant
	1,500,000	Chairman of Board	March 31, 2016		0.6		63	12 equal portions each quarter over a period of 3 years from the date of grant
	1,000,000	Chief Executive Officer	March 31, 2016		0.6		42	33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first anniversary
	1,000,000	Chief Executive Officer	August 3, 2017		0.11		28	33.33% of the stock options vest following the lapse of 12 months from the grant date, and the remaining 66.67% vest in 8 equal portions each quarter over a period of 2 years from the first anniversary
	6,200,000

(*) Date of the Company's Board of Directors' decision (or shareholders, if required).